On October 29, 2026, Xbrane Biopharma announced that the FDA approved LUCAMZI™ (ranibizumab-blrz), a biosimilar to LUCENTIS® (ranibizumab). Ranibizumab is an anti-vascular endothelial growth factor (VEGF) therapy used to treat retinal vascular disorders, including neovascular (wet) age-related macular degeneration. According to Xbrane, the approval was supported by comparative structural and…
